Cathestatin A

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Cathestatin A
• 英文别名: (2S,3S)-3-[[(2S)-1-(4-aminobutylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]oxirane-2-carboxylic acid
• 化学式: C₁₇H₂₃N₃O₅
• 分子量: 349.4
• InChiKey: ZERGYHMBBZCBJM-IHRRRGAJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  134
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Epoxysuccinic acid derivatives
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0655447A1

  公开（公告）日：1995-05-31

  A compound of the general formula: wherein R¹ represents a carboxyl group which may optionally be esterified or amidated; R² represents a cyclic group which may optionally be substituted or a polar group; n is an integer of 0 to 6; R³ represents hydrogen or a hydrocarbon residue which may optionally be substituted; R⁴ represents (1) a hydrocarbon residue which is substituted by an optionally protected amino group or (2) an alkenyl group; or R³ and R⁴ may be combined with the adjacent nitrogen atom to form a heterocyclic group containing at least two hetero atoms, or a salt thereof. The compound or a salt thereof of the present invention inhibits thiol proteases such as cathepsin L and B and serves well as a prophylactic/therapeutic agent for bone diseases such as osteoporosis.

  通式如下的化合物 其中 R¹ 代表可选择酯化或酰胺化的羧基；R² 代表可选择被取代的环状基团或极性基团；n 为 0 至 6 的整数；R³ 代表氢或可选择被取代的烃残基；R⁴代表(1)被任选保护的氨基取代的烃残基或(2)烯基；或 R³ 和 R⁴ 可与相邻的氮原子结合形成至少含有两个杂原子的杂环基团或其盐。 本发明的化合物或其盐可抑制硫醇蛋白酶，如 cathepsin L 和 B，可作为骨质疏松症等骨病的预防/治疗药物。
• Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy
  申请人：Geneste Herve

  公开号：US20060159678A1

  公开（公告）日：2006-07-20

  The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin α v β 3 receptor antagonists for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin α v β 3 receptor antagonist, for the treatment or prevention of inflammatory or autoimmune disorders, particularly for the treatment or prevention of rheumatoid arthritis and to the pharmaceutical composition itself.

  本发明涉及将细胞因子介导的信号通路调节剂与整合素 α v β 3 受体拮抗剂用于治疗或预防疾病，特别是涉及一种药物组合物的用途，该药物组合物由细胞因子介导的信号通路调节剂和整合素 α v β 3 v β 3 受体拮抗剂，用于治疗或预防炎症性或自身免疫性疾病，特别是治疗或预防类风湿性关节炎，以及药物组合物本身。
• COMPOSITION COMPRISING A TNF-ALPHA INHIBITOR AND AN INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONIST
  申请人：Abbott GmbH & Co. KG

  公开号：EP1239877B1

  公开（公告）日：2008-01-09
• JPH00770098A
  申请人：——

  公开号：JPH00770098A

  公开（公告）日：1995-03-14
• JPH0770098A
  申请人：——

  公开号：JPH0770098A

  公开（公告）日：1995-03-14